October 22, 2011 -- The SFDA released a summary of its 2010 decisions, showing 1,000 drug approvals, 916 clinical trial approvals, and 6,294 requests for drug approvals; Zhuhai Hokai Medical Instruments raised $104.5 million in an IPO on the ChiNext Exchange; Simcere Pharma and Suzhou NeuPharma will collaborate to develop novel drugs; Amerigen Pharma partnered with Stason Pharma to develop generic oral oncology drugs; Lundbeck A/S, a Danish CNS drugmaker, established a research center in Shanghai; Medicilon will complete the pre-clinical development of SK Biopharma’s new anti-depressant; Samantha Du quietly stepped back from her duties as CEO of Hutchison MediPharma; and Shenzhen Hepalink Pharma reported its Q3 profits fell 58% because of a drop in heparin prices. More details….
Stock Symbol: (SHE: 300273) (NYSE: SCR) (CPH: LUN) (SHE: 002399)
